RSV vaccination in older adults with health conditions is cost-effective

Targeting vaccination programs for respiratory syncytial virus (RSV) to older adults with underlying health conditions is a cost-effective way to reduce disease, according to a new modelling study in CMAJ (Canadian Medical Association Journal).

RSV infections cause major illness, especially in infants and older adults, and rates of infection increase with age. There are now vaccines available to prevent disease caused by RSV in adults, and vaccination campaigns may reduce the incidence in older adults and associated health care costs.

READ MORE: Prioritizing the elderly for COVID-19 boosters reduces overall deaths

READ MORE: Waging war on ‘superbugs’ in aged care

To understand the potential impact of RSV vaccinations, researchers created a model to assess the cost-effectiveness of vaccine programs in different age groups with different medical risk. Most existing cost-effectiveness studies have focused on adults aged 60 and older, but in this study, researchers focused on adults aged 50 and older. They analyzed a combination of age-only, medical risk–only and age- plus medical risk–based vaccination strategies.

Underlying medical conditions 

“Strategies focused on adults with underlying medical conditions that place them at increased risk of RSV disease are more likely to be cost-effective than general age-based strategies,” writes Dr. Ashleigh Tuite, the Centre for Immunization Programs at the Public Health Agency of Canada and the Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, with coauthors. “We found that vaccination of older adults may be less costly and more effective than no vaccination and that vaccinating people aged 70 years and older with chronic medical conditions is likely to be cost-effective based on commonly used cost-effectiveness thresholds.”

The research team notes that in some settings with higher risk of disease and higher health care costs, such as remote communities in Canada’s north, broader vaccination programs across age groups may be cost-effective.

The study was conducted by researchers at the Public Health Agency of Canada, Ottawa; Dalla Lana School of Public Health, University of Toronto, Toronto; Faculty of Health Sciences, McMaster University, Hamilton; School of Epidemiology and Public Health, University of Ottawa, Ottawa; Public Health Ontario, Toronto; and Institut national de santé publique du Québec, Québec.

A second article https://www.cmaj.ca/lookup/doi/10.1503/cmaj.240906 provides an easy reference for clinicians on key points about RSV vaccination in older adults. In particular, the National Advisory Committee on Immunization recommends RSV vaccination for adults aged 75 years and older, and adults aged 60 years and older who are residents of nursing homes and other chronic care facilities. One dose of an RSV vaccine has been shown to offer protection against disease for at least 2 respiratory virus seasons.